NDC product
Sacubitril and Valsartan
NDC 82293-029 · Novugen Pharma (USA) LLC
Key facts
| Product NDC | 82293-029 |
|---|---|
| Proprietary name | Sacubitril and Valsartan |
| Nonproprietary name | Sacubitril and Valsartan |
| Substances | SACUBITRIL, VALSARTAN |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Novugen Pharma (USA) LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA213611 |
| Pharmacologic classes | Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Neprilysin Inhibitor [EPC], Neprilysin Inhibitors [MoA] |
| Marketing start | Jul 16, 2025 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: